WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Options
Query Language
Stem
Sort by:
List Length
Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2016051424) A FORMULATION USEFUL FOR DELIVERY OF NEURO PROTECTING AGENT
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2016/051424 International Application No.: PCT/IN2015/050124
Publication Date: 07.04.2016 International Filing Date: 29.09.2015
IPC:
A61K 9/127 (2006.01) ,A61K 36/81 (2006.01) ,A61K 9/20 (2006.01) ,A61K 9/48 (2006.01) ,A61P 9/10 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
10
Dispersions; Emulsions
127
Liposomes
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
36
Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
18
Magnoliophyta (angiosperms)
185
Magnoliopsida (dicotyledons)
81
Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
20
Pills, lozenges or tablets
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
48
Preparations in capsules, e.g. of gelatin, of chocolate
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9
Drugs for disorders of the cardiovascular system
10
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applicants: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH[IN/IN]; Anusandhan Bhawan, 2 Rafi Marg New Delhi 110001, IN
Inventors: DWIVEDI, Anil Kumar; IN
AHMAD, Hafsa; IN
KHANDELWAL, Kiran; IN
SANGWAN, Rajender Singh; IN
SANGWAN, Neelam Singh; IN
GAYEN, Jiaur Rahaman; IN
., Sarika; IN
BHADUARIA, Smrati; IN
GAUR, Suresh Pratap Singh; IN
BHOSALE, Vivek Vidyadhar; IN
RATH, Srikanta Kumar; IN
SHARMA, Sharad; IN
SHUKLA, Rakesh; IN
Agent: PHILLIPS, Prashant; IN
Priority Data:
2773/DEL/201429.09.2014IN
Title (EN) A FORMULATION USEFUL FOR DELIVERY OF NEURO PROTECTING AGENT
(FR) FORMULATION UTILE POUR L'ADMINISTRATION D'AGENT NEUROPROTECTEUR
Abstract:
(EN) The present invention relates to a formulation useful for delivery of neuro protecting agent. It also demonstrates and discloses a novel delivery system for an extract of a new chemotype of Withania sonmifera (NMITLI118RT+) for neuro- protection against cerebral stroke (signifies concentrated aqueous ethanolic extract of roots of NMITLI-118, a new chemotype of Withania somnifera, a variety of Ashwagandha, which is unique in having high root yield, possessing a uniform crop canopy and uniform composition with respect to its secondary metabolites- withanolides. It is phytochemically characterized by particular abundance of two withanolides i.e. withanone and/or withanolide A, specimens of which are kept in the herbarium of CSIR-CIMAP, Lucknow, India) (Chaurasiya ND, Sangwan RS, Mishra L N, Tuli R, Sangwan N S, Metabolic clustering of a core collection of Indian ginseng Withania somnifera Dunal through DNA, Isoenzyme, polypeptide and withanolide profile diversity-Fitoterapia 2009, 80 (8) 496-505) for neuro- protection against cerebral stroke. Broadly, the invention discloses potent and prudent therapeutic potential of a new formulation using standardized fraction NMITLI118RT+ of a new variety of Withania somnifera (Ashwagandha) for brain function restoration and protection from neurological failures. Particularly the present invention further relates to the process for the preparation of the said formulation containing Standardized NMITLI118RT+ extract, its pharmaceutical compositions, for the management of cerebral stroke. The present invention also relates to a method of treatment of cerebral stroke and comprising of administering the formulation in a predetermined doses and period.
(FR) La présente invention concerne une formulation utile pour l'administration d'agent neuroprotecteur. Elle démontre et décrit en outre un nouveau système d'administration pour un extrait d'un nouveau chimiotype de Withania sonmifera (NMITLI118RT+) pour la neuroprotection contre un accident vasculaire cérébral (ce qui signifie un extrait éthanolique aqueux concentré de racines de NMITLI-118, un nouveau chimiotype de Withania somnifera, une variété de Ashwagandha, qui est unique en ce qu'elle présente un rendement en racine élevé, possède un couvert végétal uniforme et une composition uniforme en ce qui concerne ses métabolites- withanolides secondaires. Elle est caractérisée sur le plan phytochimique par une abondance particulière de deux withanolides à savoir, la withanone et/ou le withanolide A, dont des spécimens sont conservés dans l'herbarium du CSIR-CIMAP, Lucknow, Inde (Chaurasiya ND, Sangwan RS, Mishra L N, Tuli R, Sangwan N S, Metabolic clustering of a core collection of Indian ginseng Withania somnifera Dunal through DNA, Isoenzyme, polypeptide and withanolide profile diversity-Fitoterapia 2009, 80 (8) 496-505) pour neuroprotection contre un accident vasculaire cérébral. De façon générale, l'invention décrit le potentiel thérapeutique puissant et sûr d'une nouvelle formulation utilisant une fraction standardisée NMITLI118RT+ d'une nouvelle variété de Withania somnifera (Ashwagandha) pour restauration et protection de la fonction cérébrale contre les défaillances neurologiques. En particulier, la présente invention concerne en outre le procédé de préparation de ladite formulation contenant un extrait de NMITLI118RT+ standardisé, ses compositions pharmaceutiques, pour la prise en charge d'un accident vasculaire cérébral. La présente invention concerne en outre un procédé de traitement d'un accident vasculaire cérébral et comprenant l'administration de la formulation à des doses et dans une période prédéterminées.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)